SHORT MINI FUTURE WARRANT - CUREVAC Stock

DE000GX6FKV5

Real-time BOERSE MUENCHEN 03:02:24 2024-05-20 am EDT
3.91 ^EUR	0.00%

Current month	-3.93%
1 month	-3.93%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart CUREVAC N.V.

Chart SHORT MINI FUTURE WARRANT - CUREVAC

Latest news about CUREVAC N.V.

CUREVAC : A missed opportunity	May. 02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	Apr. 26	MT
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK	Apr. 25	AQ
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	Apr. 25	MT

More news

Quotes 5-day view

Date	Price	Change
24-05-20	3.91	0.00%
24-05-17	3.91	-0.26%
24-05-16	3.92	-0.51%
24-05-15	3.94	-1.01%
24-05-14	3.98	-0.25%

Real-time BOERSE MUENCHEN

Last update May 20, 2024 at 03:02 am EDT

More quotes

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	PUT
Underlying	CUREVAC N.V.
Issuer	Goldman Sachs
WKN	GX6FKV
ISIN	DE000GX6FKV5
Date issued	2021-12-20
Strike	45.97 $
Maturity	Unlimited
Parity	10 : 1
Emission price	0.48 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	4.09 €
Lowest since issue	0.639 €
Spread	0.01 €
Spread %	0.26%

Company Profile

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Sector

More about the company

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Consensus: CureVac N.V.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.21 EUR

Average target price

9.01 EUR

Spread / Average Target

+180.68%

Consensus